Jump to main content
Jump to site search

Issue 5, 2006
Previous Article Next Article

Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

Author affiliations

Abstract

We present the design, synthesis, and biological activity of three classes of tryptamine derivatives, which are non-planar analogues of the toxic anti-cancer agent fascaplysin. We show these compounds to be selective inhibitors of CDK4 over CDK2, the most active compound 9q has an IC50 for the inhibition of CDK4 of 6 µM.

Graphical abstract: Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

Back to tab navigation

Publication details

The article was received on 19 Dec 2005, accepted on 12 Jan 2006 and first published on 01 Feb 2006


Article type: Paper
DOI: 10.1039/B518019H
Org. Biomol. Chem., 2006,4, 787-801

  •   Request permissions

    Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

    C. Aubry, A. J. Wilson, P. R. Jenkins, S. Mahale, B. Chaudhuri, J. Maréchal and M. J. Sutcliffe, Org. Biomol. Chem., 2006, 4, 787
    DOI: 10.1039/B518019H

Search articles by author

Spotlight

Advertisements